Atrix Laboratories, Inc. announced that Atrix's partner, Pfizer Inc, has completed the initial phase of clinical testing of CP-533,536 formulated in the Atrigel sustained-release drug delivery system, and is advancing the product into additional human clinical testing. Atrix continues to support the product through production of clinical supplies and consultation.

"Atrix and Pfizer have a productive and energetic collaboration and we are pleased that one of several products that we are working to develop has successfully completed initial human testing and is moving forward with additional testing," said David Bethune, Atrix's chairman and CEO.

The Atrigel drug delivery system consists of biodegradable polymers, similar to those used in biodegradable sutures, dissolved in biocompatible carriers. Following application of the liquid product into accessible tissue sites, a solid film or implant is formed. The drug encapsulated within the implant is then released in a controlled manner as the polymer matrix biodegrades with time. Depending upon the medical needs, the Atrigel system can deliver small molecules, peptides, or proteins over a time period ranging from days to months. This technology is also used in the Eligard (leuprolide acetate for injectable suspension) prostate cancer product line.

In August 2000, Atrix signed a comprehensive research and worldwide licensing agreement with Pfizer Inc, under which Pfizer evaluates certain compounds in its development pipeline using Atrix's unique drug delivery systems. As part of the agreement, Atrix retains manufacturing rights and would receive royalties based on sales of any product successfully commercialized under the agreement. CP-533,536 is the first compound under this broad strategic alliance to advance into human clinical trials.